Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade-Reference-Cited by-同舟云学术

Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade

Published:2024 Issue:5 Volume:71 Page:515-526
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Yamagami Ayana¹^ORCID,Iwama Shintaro¹^ORCID,Kobayashi Tomoko¹^ORCID,Zhou Xin¹^ORCID,Yasuda Yoshinori¹^ORCID,Okuji Takayuki¹,Ito Masaaki¹,Izuchi Tetsushi¹,Ando Masahiko²,Onoue Takeshi¹^ORCID,Miyata Takashi¹^ORCID,Sugiyama Mariko¹^ORCID,Hagiwara Daisuke¹^ORCID,Suga Hidetaka¹^ORCID,Banno Ryoichi¹³^ORCID,Arima Hiroshi¹^ORCID

Affiliation:

1. Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

2. Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya 466-8550, Japan

3. Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya 464-8601, Japan

Publisher

Japan Endocrine Society

Link

https://www.jstage.jst.go.jp/article/endocrj/71/5/71_EJ23-0480/_pdf

Reference35 articles.

1. 1 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, et al. (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9: e002435.

2. 2 Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al. (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36: 1714–1768.

3. 3 Arima H, Iwama S, Inaba H, Ariyasu H, Makita N, et al. (2019) Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr J 66: 581–586.

4. 4 Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, et al. (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40: 17–65.

5. 5 Gonzalez-Rodriguez E, Rodriguez-Abreu D, Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21: 804–816.